A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiation therapy (PLATINUM trial)

INTRODUCTION: The PACIFIC study demonstrated that durvalumab consolidation therapy significantly improved progression‐free survival (PFS) and overall survival (OS) in patients with unresectable stage III non‐small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT). However, there was...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Juwhan, Lee, Jeong Eun, Choi, Chang‐Min, Oh, In‐Jae, Lee, Kye Young, Jang, Tae Won, Lee, Seung Hyeun, Kim, Eun Young, Park, Dong Won, Park, Sun Hyo, Lee, Sung Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715807/
https://www.ncbi.nlm.nih.gov/pubmed/36259253
http://dx.doi.org/10.1111/1759-7714.14663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715807/
https://www.ncbi.nlm.nih.gov/pubmed/36259253
http://dx.doi.org/10.1111/1759-7714.14663

Ejemplares similares